Anthropic Enters Healthcare Sector With Claude AI to Accelerate Drug Discovery

Anthropic announced on October 27, 2026, that it is entering the healthcare sector to assist in the development of new medicines using its Claude AI chatbot. To support this initiative, the company acquired Mithril Medicine, a one-person biotech startup founded by Cody Tranbarger, and announced joint research partnerships with six organizations, including Bristol Myers Squibb and BigHat Biosciences.

According to the reported announcement, Tranbarger used Claude as an AI assistant to coordinate contracts, logistics, and experiments across 11 external laboratories to develop treatments for two rare forms of muscular dystrophy. The startup reportedly advanced a drug candidate from concept to mouse testing in under 18 months, with human clinical trials potentially beginning as early as late 2028 if early results hold.

Key Highlights and Reported Performance

• Error Detection: Biotech firm Enveda used Claude to review a 1,061-page manufacturing document, where the AI reportedly identified all 11 errors found by human reviewers plus seven additional issues, cutting verification time by 89 per cent from over 25 hours to under three hours.
• Regulatory Documentation: Claude drafted a complex regulatory document in four hours, a task reported to normally take about three months.
• Trial Planning: Bristol Myers Squibb used the technology to evaluate early-stage clinical trial plans, generating initial analyses from a single prompt.
• Antibody and Cell Design: BigHat Biosciences optimized antibody fragments to bind over 10 times better, Divergence Labs generated about 35,000 antibody designs for food allergy treatments in a month, and Generate Biomedicines designed cell therapies resulting in gene designs 70 per cent shorter than standard models.

New Tools and Verification

Anthropic has introduced "Claude Science," a dedicated AI workbench for scientific researchers, along with a Life Sciences Verification Programme.

Limitations and Verification

Anthropic noted that these reported achievements are currently in the preclinical stage and have not yet been proven safe or effective in human trials. Readers can verify the original announcements and developments through official corporate press releases from Anthropic and partner organizations.